Completed upsized initial public offering, including full exercise of the underwriters’ option to purchase additional shares, raising gross proceeds of $397.4 million; together with existing cash expected to fund operations into 2029 The New England Journal of Medicine published positive
THOUSAND OAKS, Calif., Aug. 06, 2026 (GLOBE NEWSWIRE) -- Latigo Biotherapeutics, Inc. (“Latigo”), a clinical-stage biopharmaceutical company committed to developing innovative non-opioid pain medicines, today announced the pricing of its upsized initial public offering of 19,200,000 shares of
Results demonstrated statistically significant pain reduction, rapid onset of analgesia, and opioid-sparing potential of investigational selective Nav1.8 inhibitor LTG-001 Marks only the second original research publication in the New England Journal of Medicine reporting clinical results for a
Veteran biopharmaceutical executive brings extensive commercial and product launch expertise THOUSAND OAKS, Calif. — July 8, 2026 — Latigo Biotherapeutics, Inc. (Latigo), a clinical-stage biopharmaceutical company committed to developing innovative non-opioid pain medicines, today announced the
Experienced chief financial officer brings deep financial and strategic leadership to Latigo’s board of directors Appointment supports continued operational growth THOUSAND OAKS, Calif. — April 8, 2026 — Latigo Biotherapeutics, Inc. (Latigo), a clinical-stage biopharmaceutical company committed to
Veteran biotech leader with more than 15 years of experience joins as Latigo advances non-opioid pain pipeline Appointment comes as Latigo builds toward late-stage development and broader corporate milestones THOUSAND OAKS, Calif. — March 3, 2026 — Latigo Biotherapeutics, Inc.